F2 and neoplasm: EphA2 inhibitors can significantly inhibit PT-positive tumor growth, indicating that PT plays an important role in the development of PT-positive ESCC, and suppression of EphA2 could be a potent therapeutic strategy for patients with PT-positive ESCC.